Andere Sprachen Disc Medicine, Inc.

Aktien

A3D063

US2546041011

IRON

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
27,55 ^USD	+3,88 %		-3,97 %	-52,30 %

08.04.	DISC MEDICINE, INC. : Stifel Nicolaus bleibt bei seiner Kaufempfehlung	ZM
02.04.	DISC MEDICINE, INC. : Leerink Partners behält die Bewertung Kaufen bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Stocks Seen -2-	02.04.
Top Midday Decliners	01.04.
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge	01.04.
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)	01.04.
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria	01.04.
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	21.03.
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024	06.03.
Disc Medicine Names Pamela Stephenson as Chief Commercial Officer	26.02.
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer	26.02.
Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer	26.02.
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	20.02.
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease	20.02.
Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease	20.02.
Disc Medicine Says Potential Blood Disease Treatment Gets FDA Orphan Drug Designation	09.02.
Disc Medicine Gets Orphan Drug Designation for Blood-Disorder Treatment	09.02.
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera	09.02.
Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera	09.02.
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer	07.02.
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Disc Medicine, Inc.

Aktien

A3D063

US2546041011

IRON

Andere Sprachen

Filter